An 8 week open-label interventional multicenter study to evaluate the lung clearance index as endpoint for clinical trials in cystic fibrosis patients ≥ 8 years of age, chronically infected with *Pseudomonas aeruginosa*

Sivagurunathan Sutharsan (✉ sivagurunathan.sutharsan@rlk.uk-essen.de)

<https://orcid.org/0000-0003-4069-4900>

Susanne Naehrig

Ludwig-Maximilians-Universitat Munchen

Uwe Mellies

Universitat Duisburg-Essen

Christian Sieder

Novartis Pharma GmbH

joerg Zeigler

Novartis Pharma GmbH

Research article

Keywords: cystic fibrosis, forced expiratory volume in 1 second, lung clearance index, tobramycin, *Pseudomonas aeruginosa*, antibiotics, clinical trials

Posted Date: March 12th, 2020

DOI: <https://doi.org/10.21203/rs.3.rs-15870/v2>

License: © ⓘ This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Version of Record: A version of this preprint was published at BMC Pulmonary Medicine on June 12th, 2020. See the published version at <https://doi.org/10.1186/s12890-020-01201-y>.

Abstract

Background Forced expiratory volume in 1 second (FEV₁) is the only parameter currently recognized as a surrogate endpoint in cystic fibrosis (CF) trials. However, FEV₁ is relatively insensitive to changes in the small airways of patients with milder lung disease. This pilot study aimed to evaluate the lung clearance index (LCI) as a marker for use in efficacy trials with inhaled antibiotics in CF. **Methods** This open-label, single-arm study enrolled CF patients with *Pseudomonas aeruginosa* infection, who were treated with tobramycin (28-day on/off regime). FEV₁, LCI and bacterial load in sputum (CFU) were assessed at baseline, after 1, 4 and 8 weeks of treatment. **Results** All patients (n=17) showed elevated LCI of >11 despite 3 patients having normal FEV₁ (>90% predicted) at baseline. Overall, LCI improved in 8 (47%) patients and FEV₁ in 9 (53%) patients. At week 4, LCI improved by 0.88, FEV₁ increased by 0.52%, and *P. aeruginosa* reduced by 30481.3 CFU/mL. These changes were however statistically non-significant. Six adverse events occurred in 5/17 (29.4%) patients, most of which were mild-to-moderate in severity. **Conclusions** Due to the low evaluable sample size, no specific trend was observed related to the changes between LCI, FEV₁ and CFU. Based on the individual data from this study and from recently published literature, LCI has been shown to be a more sensitive parameter than FEV₁ for lung function. LCI can be hypothesized to be an appropriate endpoint for efficacy trials in CF patients if the heterogeneity in lung function is limited by enrolling younger patients or patients with more milder lung disease and thus, limiting the ventilation inhomogeneities. **Trial registration** : The study is registered with ClinicalTrials.gov, identifier: NCT02248922

Background

Cystic fibrosis (CF) is a life-limiting, autosomal recessive genetic disease [1], characterized by a reduced quantity and/or function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, leading to an impaired mucociliary clearance of the airways, followed by chronic inflammation, infection and thus progressive and irreversible loss of lung function [2]. The main driver of lung function decline beyond infancy in people with CF is the chronic infection with *Pseudomonas aeruginosa* [3]. Although it is a complex multiorgan and multifactorial disease, the chronic lung infection by *P. aeruginosa* is the primary cause of morbidity. Therefore, an antibiotic maintenance therapy is the preferred standard treatment in these patients. [2]. Inhaled tobramycin typically given in 28 day cycles of one month on and one month off periods, is recommended for treating individuals with CF aged ≥6 years, who have mild to moderate lung disease with persistent *P. aeruginosa* infection [4].

Currently, forced expiratory volume in one second (FEV₁) and rate of FEV₁ decline are the only accepted surrogate markers for assessing lung function decline [5]. However, with significant advances in the care of patients with CF, such as the newly introduced CFTR-targeted therapies and considerable improvement in survival rates, the rate of decline in FEV₁ has slowed [6, 7], leading to a preservation of spirometric lung function within the normal range into young adulthood [8, 9]. Moreover, FEV₁ is insensitive during early stages of lung disease resulting in normal spirometry findings, despite the progression of structural

damage in lungs, for example in bronchiectasis. Therefore, the reliability on FEV₁ as an indicator of disease progression especially in the early stages of lung disease has become questionable [9, 10]. Increasing evidence suggest that in patients with CF, pulmonary deterioration starts early in life and can occur in the absence of respiratory symptoms at normal lung function in terms of FEV₁ [11]. Thus, there is a need for early intervention before onset of irreversible lung damage based on alternative clinically sensitive surrogate markers for detection of early CF lung disease [12].

A multiple breath washout (MBW) test assessing ventilation inhomogeneity has been shown to be a sensitive lung function test to detect early pathology in patients with CF [12]. The most commonly reported MBW outcome is the lung clearance index (LCI), which is a robust, noninvasive technique to detect early lung disease changes across all age groups [13, 14]. Consequently, LCI has been evaluated as a new sensitive surrogate endpoint for measuring trial outcomes focusing on the early stages of disease [13]. LCI was used for the first time as the primary study endpoint in a pivotal trial in children (6–11 years) with CF treated with an oral combination of CFTR modulators, lumacaftor (LUM) and ivacaftor (IVA). Treatment with LUM/IVA, demonstrated a statistically significant improvement in lung function, as measured by LCI_{2.5} and percent predicted FEV₁ (ppFEV₁), versus placebo in children with CF homozygous for F508del-CFTR [15]. However, there is still very limited data available on the use of LCI as a clinical endpoint for CF patients treated with inhaled antibiotics. Recent evidence from longitudinal studies also suggest a between-visit variability in the LCI with increasing severity of the lung disease [16].

The aim of the present study was to examine the clinical utility of LCI for assessing short-term clinical response to inhaled tobramycin antibiotic therapy in patients with CF positive for *P. aeruginosa*, aged 6 years and older with mild to moderate lung disease.

Methods

Study design and patients:

This was an open-label, single arm study in CF patients with chronic *P. aeruginosa* infection. The study consisted of screening period (5 to 26 days) to test the presence of *P. aeruginosa* (Visit 1), a baseline visit (Visit 2), a visit one week after baseline visit (Visit 3), followed by a visit after 28 days on-treatment period (Visit 4) and subsequently a visit after 28 days off-treatment period (Visit 5, end of study). All patients were treated with tobramycin monotherapy, either as an inhalation solution (TIS) 300 mg twice daily (BID) or as an inhalation powder (TIP) 128 mg BID. FEV₁, LCI and bacterial load in sputum (colony forming units [CFU]) were assessed at baseline, after 1, 4 and 8 weeks of treatment. Spirometric and LCI assessments were conducted before or at least one hour after the inhalation of the drug. MBW measurements to assess the LCI were performed with the ExhalyzerD (Eco Physics GmbH, Munich, Germany). The study design was approved by the independent ethics committee and institutional review boards; and was in accordance with the Declaration of Helsinki.

The study enrolled patients from seven sites in Germany, diagnosed with CF aged 6 to 50 years, with a chronic infection of airways with *P. aeruginosa* within the last 12 months and at screening. Patients with an elevated LCI of ≥ 7.5 [17] and FEV₁ of $\geq 50\%$ at screening, and those receiving inhaled tobramycin monotherapy in 28 days on/off regime in the past 3 month before screening were included. Informed consent was obtained from patients for having their data collected. Patients receiving more than one class of inhaled antipseudomonal antibiotic during the study or in the past 56 days prior to the baseline visit, or who used oral or intravenous antipseudomonal antibiotics within 28 days prior to the on-phase of the study drug or loop diuretics within 7 days prior to the first study medication administration, were excluded.

Study assessments

The primary endpoint was change in LCI after 4 weeks of treatment versus baseline. Secondary endpoints included change in FEV₁ and CFU after week 4 following treatment; change of LCI after week 1 following treatment; change of LCI, FEV₁ and CFU between week 4 (end of the study drug inhalation in the current treatment cycle) and week 8 (prior to the start of the study drug inhalation in the following treatment cycle); and correlation between the changes of LCI, FEV₁ and CFU after weeks 1, 4 and 8 versus baseline, respectively.

For LCI assessment, the multiple breath washout device Exhalyzer D (Ecomedics, Zurich, Switzerland) was used, with Nitrogen as the tracer gas. All equipment and the device software were identical throughout the sites. LCI was determined according to the Exhalyzer D MBW SOP of the manufacturer that is based on the current MBW guidelines of the European Cystic Fibrosis Society (ECFS), and all study sites were provided with a device specific training before start of the study.

The mean of two acceptable MBW measurements was used for analysis if the coefficient of variation (CV) for LCI was $\leq 5\%$, else another MBW measurement was performed (functional residual capacity [FRC] not $>25\%$). The mean of three acceptable MBW measurements was used, if the CV for LCI was $\leq 10\%$ (FRC not $>25\%$). One more MBW measurement was to be performed otherwise. MBW was repeated four times, and the mean of two measurements with the smallest difference in LCI was used. A single result could only be used if only one technically acceptable result was obtained in four measurements. If no single acceptable result was obtained in four measurements, test sessions were continued (within reason) until one technically sound trial was obtained. Single MBW assessments were stopped immediately if more than one cough event occurred during the wash-out phase, if there was a continuous decrease of the carbon dioxide concentration for >60 seconds, and if there was a change in the breathing pattern of more than 20%. For the measurements used to calculate the mean value, a quality control was done by a central assessor (MBW specialist of the manufacturer).

Statistical analysis

Assuming a change of 5% in FEV₁ with an intraindividual standard deviation of 9% between the on- and off-treatment cycles, 28 patients would provide 80% power on a 2-sided 5% significance level to detect this change. To compensate for protocol deviations and dropouts, 35 patients were planned to be recruited into this trial. All variables were summarized using descriptive statistics. Analyses were performed by using SAS Version 9.4.

Changes in LCI from baseline were analyzed using an analysis of variance (ANOVA) model. Estimates over time were presented as least squares (LS)-means, pairwise LS-mean differences along with 95% confidence intervals (CI) and 2-sided p-values for the pairwise differences between visits. If the baseline value was missing, then change was calculated from the data recorded at the screening. The primary analysis included patients with a valid observation at the baseline and post-baseline visits.

Results

In total, 17 patients (5 patients treated with TIS and 12 patients with TIP) were enrolled and completed the study. The majority of the patients (14 patients, 82.4%) were aged >17 years, with an overall mean age of 26.4±9.99 years and body mass index (BMI) of 21.1±2.46 kg/m². The study had a higher proportion of men (64.7%) versus women (35.3%). All patients had complete data on LCI and FEV₁. Not all patients were able to expectorate sputum and thus, complete CFU data were only available for 10 patients. At baseline, mean LCI was 17.99±4.73 (95% CI: 11.16–29.14) and FEV₁ was 76.96±18.60% predicted (95% CI: 44.66–115.5) (**Figure 1a**). All patients demonstrated considerably elevated LCI of >11 (normal range 6.5–7.5) despite 3 patients having a normal lung function (FEV₁ >90% predicted) at baseline. The demographics and characteristics of patients at the baseline are presented in **Table 1**.

The mean LCI improved slightly over time from baseline. At week 4, LCI improved by 0.88 (17.10±0.84; 95% CI: 15.31–18.88) from baseline, which was statistically non-significant (p=0.41). Overall, 8 (47%) patients showed an improved LCI at week 4 from baseline. At least 3 patients showed worsening of LCI despite improvement in FEV₁ (**Table 2**).

The mean FEV₁ increased by 0.52% (77.48±20.56; 95% CI: 66.91–88.05) at week 4 from baseline, which was not statistically significant (p=0.70). At week 4, 9 patients (53%) showed an improved FEV₁ and *P. aeruginosa* reduced by 30481.3 CFU/mL (26113.0 CFU/mL; 95% CI: (–32035.02–84261.05) as compared to baseline (56594.3). However, the change in CFU was not statistically significant (p=0.35). The mean LCI improved slightly (–0.479) after 1 week of drug inhalation (p=0.59). The changes in LCI (p=0.42), FEV₁ (p=0.39), and CFU (p=0.35) from week 4 to week 8 were statistically non-significant (**Figure 1b-d**). A statistically significant positive correlation was observed between LCI and CFU at week 1 (r=0.59, p=0.0321) and week 4 (r=0.79, p=0.0046) from baseline. A negative correlation (r=–0.64) was seen between FEV₁ and CFU at week 4 from baseline, which was statistically significant (p=0.0462).

Overall, 6 adverse events (AEs) occurred in 5/17 patients (29.4%) (3 patients on TIP and 2 patients on TIS), most of which were related to respiratory, thoracic and mediastinal disorders (n=3, 17.6%). Most of

these were mild or moderate in severity (**Table 3**).

Discussion

It has been shown that lung damage induced by inflammation precedes FEV₁ decline [10]. LCI derived from MBW reflects ventilation defects in the respiratory tract, including the early dysfunction in small airways, which are not easily identified with traditional spirometry methods [13]. Therefore, the present study assessed the clinical utility of LCI for assessing the response to inhaled tobramycin antibiotic therapy (both nebulised and powder inhalers) in patients with CF positive for *P. aeruginosa*. The use of both nebulized and powder inhalers in this study was based on evidence from previous non-inferiority studies suggesting similar efficacy between the two aerosol therapies [18]. In the present study, three patients had a significantly elevated LCI despite having a normal FEV₁ % at baseline. In addition, relative changes in LCI at week 4 versus baseline for individual patients were higher than the respective FEV₁ differences (**Table 2** and **Figure 2**), indicating a higher sensitivity of lung function assessment with MBW compared to classical spirometry. Similar findings from previously published data also showed that LCI provides a more sensitive overall estimate of ventilation inhomogeneity compared to FEV₁, at least in patients with mild lung disease [19].

There is increasing evidence on the clinical utility of LCI. In addition to LCI being used as a clinical endpoint [5, 15], it has also been used to assess mucociliary clearance in young children [20] treated with CFTR-modulators [15] and to monitor disease progression [21], or both [22]. However, this study with inhaled tobramycin demonstrated that changes in LCI, FEV₁ and CFU at week 1, 4 and 8 were not statistically significant. There was no specific trend observed with respect to correlation between the changes of LCI, FEV₁ and CFU after week 1, 4 and 8 versus baseline. This may be attributed to the heterogeneity in LCI response to antibiotic treatment seen in the individual data for MBW and spirometry shown in **Figure 2**. These results are in line with previously published studies [23, 24] and pooled analyses [25]. Despite the use of a more efficient therapy (inhaled formulation) in terms of an increased bioavailability of tobramycin in sputum we observed heterogeneity in the present study which is comparable to the findings seen with intravenous antibiotic treatment in children with CF [23]. In contrast to the outcome from the present study, a short-term study (one month) with 32 CF children on intravenous antibiotic treatment showed a significant improvement in LCI compared with FEV₁ [26]. However, data about LCI as outcome measure for short-term efficacy of antibiotics in CF remains very limited.

The observed heterogeneity in lung function response to therapy can partly be attributed to the non-responders, which could be due to a few patients becoming refractory to inhaled antibiotics [27]. Further, there were single cases of negative, or positive change in CFU in some patients however, such findings are not conclusive, also because not all patients were able to expectorate sputum and thus, CFU data was missing for some patients. In addition, CFU assessment in general is characterized by huge intraindividual variation and therefore, any non-significant findings have to be evaluated with caution. Based on this data, one may speculate that therapy response in these patients with mild to moderate lung

disease, chronically treated with inhaled tobramycin was weak and/or heterogeneous. At least 3 patients showed worsening of LCI despite an improvement in FEV₁, which could be due to increased ventilation inhomogeneity in newly ventilated lung regions following inhaled antibiotic therapy (eg. by reduced air-trapping) [24, 28]. However, it is important to note that the small evaluable sample size of the present study makes it challenging to draw clear conclusions.

In addition, chest physiotherapy to remove sticky mucus from the airways, prior to lung function testing may also lead to heterogeneity in LCI response. The inherent ventilation inhomogeneity combined with the clearance of mucus plugged airways (after chest physiotherapy) which were previously poorly ventilated (at baseline) leads to an increased LCI [29]. Indeed, a mean reduction of 0.2 in LCI response 30 min after physiotherapy was observed in CF patients with lung disease of varying severity, suggesting unpredictability of short-term physiotherapy on LCI responses [30]. Similar to previously reported studies, the standard physiotherapy performed in the present study is strongly dependent on the therapist's discretion as well as on the daily performance and adherence of the individual CF patient. Although chest physiotherapy is typically performed before inhalation and is done at least 1h prior to MBW, there is no guidance on the timing for the physiotherapy at each visit. Hence, chest physiotherapy could have affected the outcome of lung function testing in this study to a certain degree. A detailed documentation of the timing and type of physiotherapy relative to MBW lung function testing in future clinical trials using LCI as a study endpoint is therefore recommended [29].

Based on the results from the present study as well as from available literature, it can be hypothesized that LCI can be an appropriate endpoint for efficacy trials in CF patients if the heterogeneity in lung function is limited by enrolling younger patients or patients with more milder lung disease and thus, limited ventilation inhomogeneities. Furthermore, including younger patients with milder lung disease and specifically defined time points for chest physiotherapy; while excluding false negative changes in lung function outcomes resulting from physiotherapy is recommended.

During the study period six AEs were reported, all of which were mild and moderate in severity, which is in line with previously published phase III data [31, 32] and the clinical experience with inhaled tobramycin.

A major limitation of the present study is the small sample size because of difficulties with patient enrollment and recruitment. The standard of care changed during the setup of the study, i.e., the majority of *P. aeruginosa* positive CF patients were to be treated with continuous inhaled sequential antibiotic combinations [33]. Hence, enrollment of patients on monotherapy was a challenge and thus, the study could include only 17 patients versus 35 patients that were planned to be enrolled. This was the primary reason for the premature termination of the study.

Conclusions

In summary, the changes in LCI, FEV₁ and CFU were statistically non-significant at week 1, 4 and 8 when compared with baseline which may be due to the heterogeneity in LCI response to antibiotic treatment

and the low evaluable sample size.

Even if LCI is not identified as the ideal clinical efficacy endpoint for studies with antibiotic treatment (either intravenous or inhaled), it does not jeopardize the overall value of LCI as a more sensitive lung function parameter for CF patients with mild to moderate lung disease. Considering previously published data, LCI seems to be a suitable endpoint for drugs affecting the mucociliary clearance and to assess disease progression in cystic fibrosis. However, LCI alone does not seem to be the ideal clinical endpoint for efficacy studies with antibiotic treatment (either intravenous or inhaled) in small groups of CF patients.

List Of Abbreviations

AE	Adverse events
ANOVA	Analysis of variance
BID	Twice daily
BMI	Body mass index
CF	Cystic fibrosis
CFTR	Cystic fibrosis transmembrane conductance regulator
CFU	Colony forming units
CI	Confidence intervals
d	Difference
FEV1	Forced expiratory volume in one second
IVA	Ivacaftor
LCI	Lung clearance index
LS	Least squares
LUM	Lumacaftor
MBW	Multiple breath washout
<i>P. aeruginosa</i>	<i>Pseudomonas aeruginosa</i>
ppFEV1	Percent predicted FEV ₁
SD	Standard deviation
TIP	Tobramycin inhalation powder
TIS	Tobramycin inhalation solution

Declarations

Availability of data and materials: The data generated during and/or analyzed during the current study are available from the corresponding author upon reasonable request.

Ethics declarations:

Ethics approval and consent to participate: The study design was approved by the independent ethics committee and institutional review boards (Supplementary material); and was in accordance with the Declaration of Helsinki. Informed consent was obtained from each patient (or from parents for children <16 years of age) in writing before randomization.

Consent for publication: Not applicable.

Competing interests: SS has served as an investigator in clinical trials for Galapagos, Proteostasis, Celtaxsys, Flatley, Novartis Pharma GmbH and Vertex Pharmaceuticals Incorporated and has consulted for Teva GmbH, Novartis Pharma GmbH, Chiesi GmbH and Vertex Pharmaceuticals Incorporated. SN and UM have nothing to disclose. CS and JZ are employees of Novartis Pharma GmbH.

Funding: The funding for study design, data collection, analysis, and interpretation was provided by Novartis Pharma GmbH. Medical writing support for the manuscript, in accordance with Good Publication Practice (GPP3) guidelines (<http://www.ismpp.org/gpp3>) was funded by Novartis Healthcare Pvt. Ltd, Hyderabad, India.

Author contributions: All authors assume responsibility for the accuracy of the data interpretation and approved the manuscript for publication. UM, CS, and JZ contributed to study conception, protocol development, data analysis and interpretation of data. SN and UM contributed on the interpretation of data and critical review of the study, SS and JZ drafted the first version of the manuscript. All authors helped with the review and finalization of the manuscript.

Acknowledgements: The authors thank Nihal Maremanda and Lakshmi Deepa (Novartis Healthcare Private Ltd, Hyderabad, India) for medical writing support and Mirjam Stahl, Division of Pediatric Pulmonology and Allergy and Cystic Fibrosis Center, Department of Pediatrics, University of Heidelberg, Germany, for discussion of the LCI data

References

1. Riordan JR, Rommens JM, Kerem B, Alon N, et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. *Science*. 1989;245:1066-73.
2. Elborn JS. Cystic fibrosis. *Lancet*. 2016;388:2519-31.
3. Langton Hewer SC and Smyth AR. Antibiotic strategies for eradicating *Pseudomonas aeruginosa* in people with cystic fibrosis. *Cochrane Database Syst Rev*. 2017;4:CD004197.

4. Smith S, Rowbotham NJ, Regan KH. Inhaled anti-pseudomonal antibiotics for long-term therapy in cystic fibrosis. *Cochrane Database Syst Rev*. 2018;3:CD001021.
5. Stanojevic S, Ratjen F. Physiologic endpoints for clinical studies for cystic fibrosis. *J Cyst Fibros*. 2016;15:416-23.
6. Pittman JE, Davis SD. Decline in Forced Expiratory Volume in 1 Second in Cystic Fibrosis-Watch the Pendulum Swing. *J Pediatr*. 2016;169:7-9.
7. Konstan MW, McKone EF, Moss RB, Marigowda G, et al. Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. *Lancet Respir Med*. 2017;5:107-18.
8. Sawicki GS, McKone EF, Pasta DJ, Millar SJ, et al. Sustained benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data. *American journal of respiratory and critical care medicine*. 2015;192:836-42.
9. Mott LS, Park J, Murray CP, Gangell CL, et al. Progression of early structural lung disease in young children with cystic fibrosis assessed using CT. *Thorax* 2012;67:509-16.
10. Breuer O, Caudri D, Stick S, Turkovic L. Predicting disease progression in cystic fibrosis. *Expert Rev Respir Med*. 2018;12:905-17.
11. Judge EP, Dodd JD, Masterson JB, Gallagher CG. Pulmonary abnormalities on high-resolution CT demonstrate more rapid decline than FEV1 in adults with cystic fibrosis. *Chest*. 2006;130:1424-32.
12. Subbarao P, Milla C, Aurora P, Davies JC, et al. Multiple-Breath Washout as a Lung Function Test in Cystic Fibrosis. A Cystic Fibrosis Foundation Workshop Report. *Ann Am Thorac Soc*. 2015;12:932-9.
13. Kent L, Reix P, Innes JA, Zielen S, et al. Lung clearance index: evidence for use in clinical trials in cystic fibrosis. *J Cyst Fibros*. 2014;13:123-38.
14. Horsley AR, Gustafsson PM, Macleod KA, Saunders C, et al. Lung clearance index is a sensitive, repeatable and practical measure of airways disease in adults with cystic fibrosis. *Thorax*. 2008;63:135-40.
15. Ratjen F, Hug C, Marigowda G, Tian S, et al. Efficacy and safety of lumacaftor and ivacaftor in patients aged 6-11 years with cystic fibrosis homozygous for F508del-CFTR: a randomised, placebo-controlled phase 3 trial. *Lancet Respir Med*. 2017;5:557-567. Epub 2017 Jun 9.
16. Green K, Kongstad T, Skov M, Buchvald F, et al. Variability of monthly nitrogen multiple-breath washout during one year in children with cystic fibrosis. *J Cyst Fibros*. 2018;17(2):242-248.
17. Houtz B, Green K, Lindblad A, Singer F, et al. Tidal N2 washout ventilation inhomogeneity indices in a reference population aged 7-70 years *European Respiratory Journal* 2012;40:P3797.
18. Tiddens HA, Bos AC, Mouton JW, Devadason S, et al. Inhaled antibiotics: dry or wet? *Eur Respir J*. 2014;44(5):1308-18.
19. Davies JC, Sheridan H, Lee P-S, Song T, et al. Effect of ivacaftor on lung function in subjects with CF who have the G551DCFTR mutation and mild lung disease: a comparison of lung clearance index

- (LCI) vs. spirometry. *J Cyst Fibros.* 2012;11(Suppl. 1):S15.
20. Davies J, Sheridan H, Bell N, Cunningham S, et al., Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551DCFTR mutation and preserved spirometry: a randomised controlled trial. *Lancet Respir. Med.* 2013;1:630-8.
 21. Svedberg M, Gustafsson PM, Robinson PD, Rosberg M, et al. Variability of lung clearance index in clinically stable cystic fibrosis lung disease in school age children. *J Cyst Fibros.* 2018;17:236-41.
 22. Ellemunter H, Eder J, Fuchs S, Gappa M, et al. Long-term improvement of lung clearance index in patients with mild cystic fibrosis lung disease: Does hypertonic saline play a role? *J Cyst Fibros.* 2016 Jan;15(1):123-6.
 23. Welsh L, Nesci C, Tran H, Tomai M, et al. Lung clearance index during hospital admission in school-age children with cystic fibrosis. *J Cyst Fibros.* 2014;13:687-91.
 24. Yamine S, Bigler A, Casaulta C, Singer F, et al. Reasons for heterogeneous change in LCI in children with cystic fibrosis after antibiotic treatment. *Thorax.* 2014;69:183.
 25. Sonneveld N, Stanojevic S, Amin R, Aurora P, et al. Lung clearance index in cystic fibrosis subjects treated for pulmonary exacerbations. *Eur Respir J.* 2015;46:1055-64.
 26. Hatziagorou E, Avramidou V, Kirvassilis F, Tsanakas J. Use of lung clearance index to assess the response to intravenous treatment in cystic fibrosis. *Hippokratia.* 2015;19:47-52.
 27. VanDevanter DR, Ballmann M, Flume PA. Applying clinical outcome variables to appropriate aerosolized antibiotics for the treatment of patients with cystic fibrosis. *Respiratory Medicine.* 2011;105: S18-S23.
 28. Robinson PD, Goldman MD, Gustafsson PM. Inert gas washout: theoretical background and clinical utility in respiratory disease. *Respiration.* 2009;78:339-55.
 29. Grosse-Onnebrink J, Mellies U, Olivier M, Werner C, et al. Chest physiotherapy can affect the lung clearance index in cystic fibrosis patients. *Pediatr Pulmonol.* 2017;52:625-31.
 30. Pflieger A, Steinbacher M, Schwantzer G, Weinhandl E, et al. Short-term effects of physiotherapy on ventilation inhomogeneity in cystic fibrosis patients with a wide range of lung disease severity. *J Cyst Fibros.* 2015;14:627-31.
 31. Ramsey BW, Pepe MS, Quan JM, Otto KL, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. *N Engl J Med.* 1999;340:23-30.
 32. Konstan MW, Flume PA, Kappler M, Chiron R, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. *J Cyst Fibros.* 2011;10:54-61.
 33. Dasenbrook EC, Konstan MW, VanDevanter DR. Association between the introduction of a new cystic fibrosis inhaled antibiotic class and change in prevalence of patients receiving multiple inhaled antibiotic classes. *J Cyst Fibros.* 2015;14:370-5.

Tables

Table 1. Patient demographics and baseline characteristics (N=17)

Age, years	26.4 (9.99)
Men, n (%)	11 (64.7)
Height, cm	171.12 (12.8)
Weight, kg	62.6 (12.9)
Waist circumference, cm	85.1 (22.6)
BMI, kg/m ²	21.1 (2.5)
LCI	17.99 (4.7)
FEV ₁ (%)	76.96 (18.6)

Data are expressed as mean (SD) unless indicated otherwise.

BMI, body mass index; FEV₁, forced expiratory volume in one second; LCI, lung clearance index; SD, standard deviation

Table 2. Lung function parameters after visit 4 versus baseline

Patient #	Age	FEV ₁ at baseline (% predicted)	dLCI in % of baseline	dFEV ₁ in % of baseline	dCFU [/g]
1	17	82.6	29.8%	11.0%	-17,120
2	17	84.7	3.8%	10.6%	-
3	37	71.5	-42.4%	7.2%	-224,700
4	19	68.2	-24.6%	7.0%	-
5	19	115.5	-19.8%	4.4%	-
6	24	109.9	10.5%	2.7%	-12,200
7	35	77.8	-3.0%	2.1%	-12,640
8	37	79.5	6.7%	0.9%	-40
9	22	44.7	-24.1%	0.6%	20,800
10	18	65.9	-4.8%	0.0%	-225,600
11	41	61.9	-4.6%	0.0%	-8,800
12	30	51.5	-15.6%	-1.0%	100
13	8	88.9	-6.9%	-2.2%	732
14	43	101.1%	8.7%	-5.1%	14,000
15	34	67.9%	17.1%	-6.9%	-10,040
16	23	75.3%	4.8%	-12.5%	29,600
17	24	68.6%	36.2%	-13.0%	-

CFU, colony forming units; d, difference at week 4 versus baseline; FEV₁, forced expiratory volume in one second; LCI, lung clearance index.

Table 3: Adverse event

System organ class	TIS (N=5) n (%)	TIP (N=12) n (%)	Overall (N=17) n (%)
Any MedDRA system organ class	2 (40.0)	3 (25.0)	5 (29.4)
Injury, poisoning and procedural complications	1 (20.0)	0 (0.0)	1 (5.9)
Sunburn	1 (20.0)	0 (0.0)	1 (5.9)
Investigations	1 (8.3)	0 (0.0)	1 (5.9)
Forced expiratory volume decreased	1 (8.3)	0 (0.0)	1 (5.9)
Respiratory, thoracic and mediastinal disorders	2 (16.7)	1 (20.0)	3 (17.6)
Cough	1 (8.3)	0 (0.0)	1 (5.9)
Haemoptysis	0 (0.0)	1 (20.0)	1 (5.9)
Obstructive airways disorder	1 (8.3)	0 (0.0)	1 (5.9)

TIS, Tobramycin inhalation solution; TIP, Tobramycin inhalation powder. Percentages are based on N of each group in safety set. A patient with multiple occurrences of an AE is counted only once in the AE category. A patient with multiple adverse events within a primary system organ class is counted only once in each system organ class total row. MedDRA version 20.0 has been used for coding of adverse events.

Figures

Figure 1: Lung function parameters (LCI and FEV₁) and CFU at baseline and over time

Figure 1

Lung function parameters (LCI and FEV1) and CFU at baseline and over time. CFU, colony forming units; FEV1, forced expiratory volume in one second; LCI, lung clearance index; SD, standard deviation

Figure 2: Matched pairs of relative changes in LCI and FEV₁ at week 4 from baseline

Figure 2

Matched pairs of relative changes in LCI and FEV1 at week 4 from baseline. d, difference; FEV1, forced expiratory volume in one second; LCI, lung clearance index

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [Supplementarymaterial.docx](#)